ADPT compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

ADPTAdaptive Biotechnologies Corp

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

ADPTAdaptive Biotechnologies Corp

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ADPT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±15.2%▲+7.18%×0.47

Q1 FY26±16.2%▲+4.72%×0.29

Feb 6 '26±13.4%▼−4.25%×0.32

Jan 12 '26±13.5%▲+15.86%×1.18

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

= impliedADPT realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

Feb 4 '26

±3.7%

▲+8.15%

×2.22

Q3 FY25±3.7%▲+7.81%×2.11

ADPTAdaptive Biotechnologies Corp

25.04▼−6.02%· post 25.04· delayed

Mkt cap$4.3BRevenue$72MQ2 FY26Revenue$277MFY25

AMGNAmgen Inc

465.45▼−0.12%· post 467.48· delayed

After hoursNov 2 '26delayed

Mkt cap$251.9BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

Compare

After hoursNov 2 '26delayed

ADPTAdaptive Biotechnologies Corp

AMGNAmgen Inc

25.04▼−6.02%post 25.04delayed

Price

465.45▼−0.12%post 467.48delayed

$4.3B

Mkt cap

$251.9B

Q2 FY26$72M

Revenue

$10.1BQ2 FY26

FY25$277M

Revenue

$36.8BFY25

ADPT25.04▼−6.02%vsAMGN465.45▼−0.12%After hoursNov 2 '26delayed